Thousands of men are set to receive a groundbreaking prostate cancer treatment through the NHS in the coming weeks. Patients with localized cancer will now have access to abiraterone in England as part of an expanded healthcare initiative. Approximately 2,000 individuals diagnosed in the last three months will be eligible for the drug, with an additional 7,000 men each year expected to meet the criteria.
Abiraterone, an oral medication, works by depriving cancer cells of the essential hormones needed for growth, effectively halting the spread of the disease. NHS research indicates that the survival rate after six years on abiraterone was 86%, a significant improvement compared to the standard treatment’s 77% survival rate.
Prostate cancer is the most prevalent cancer among men and the second most common overall in the UK, with over 55,000 new cases reported annually. Cancer Research UK reports these statistics. The recent approval of abiraterone for more patients reflects the government’s commitment to combating the disease, as stated by Health and Social Care Secretary Wes Streeting.
The National Clinical Director for Cancer at NHS England, Professor Peter Johnson, highlighted the life-changing impact of this treatment option on thousands of men with prostate cancer. The introduction of the life-extending drug on the NHS will offer hope to many patients by potentially extending their lifespan and improving their overall health.
A revolutionary blood test being developed by researchers at the University of Cambridge may soon provide a more accurate assessment of prostate cancer presence, aggressiveness, and the necessity for treatment. This innovative test detects DNA methylation markers released by tumors, enabling doctors to evaluate cancer status and severity more efficiently than before. Men who previously underwent the PSA test could benefit from this new blood test without the need for invasive biopsy procedures.
For quick access to valuable news content, select Daily Mirror as a ‘Preferred Source’ on Google News.